Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5224049 | 0.93 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL5361729 | 0.89 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL5511877 | 0.88 | HDAC8 (0.36) | HSD17B10SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL6843843 | 0.81 | NR1H2 (0.37) | HSD17B10SMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL4872655 | 0.81 | NR1H2 (0.37) | HSD17B10SMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL5984320 | 0.80 | HDAC8 (0.38) | HSD17B10SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL2126924 | 0.79 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL31148270 | 0.79 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL10215476 | 0.79 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL18591178 | 0.78 | HSD17B10 (0.39) | HSD17B10SMN1; SMN2ALDH1A1SPHK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361743-B2 | Such as 5-propyl-azepane-2-carboxylic acid [2-chloro-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydro-pyran-2-yl)-propyl]-amide; for prevention and treatment of mycobacterial, mycoplasmal or chlamydia infection; microbiocides | PFIZER INC (US) | 2008-04-22 | — | — | US | disclosed |
| US-7256177-B2 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| EP-1814893-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-7199106-B2 | Lincomycin derivatives possessing antimicrobial activity | VICURON PHARMACEUTICALS, INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-20060148722-A1 | Novel lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-07-06 | — | — | US | disclosed |
| WO-2006055070-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| EP-1644393-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIMICROBIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050215488-A1 | Such as 5-propyl-azepane-2-carboxylic acid [2-chloro-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydro-pyran-2-yl)-propyl]-amide; for prevention and treatment of mycobacterial, mycoplasmal or chlamydia infection; microbiocides | VICURON PHARMACEUTICALS INC. | 2005-09-29 | — | — | US | disclosed |
| US-20050043248-A1 | Novel lincomycin derivatives possessing antimicrobial activity | VICURON PHARMACEUTICALS INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005012320-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIMICROBIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148722-A1 | Novel lincomycin derivatives possessing antibacterial activity | LCLAT1, LAS1L, NRDC | HSD17B10 1397/4885SMN1; SMN2 4232/4885MEN1 4303/4885 |
| US-20050215488-A1 | Such as 5-propyl-azepane-2-carboxylic acid [2-chloro-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydro-pyran-2-yl)-propyl]-amide; for prevention and treatment of mycobacterial, mycoplasmal or chlamydia infection; microbiocides | PAM, MLYCD, PPT1 | HSD17B10 1865/4885SMN1; SMN2 3752/4885MEN1 3653/4885 |
| US-20050043248-A1 | Novel lincomycin derivatives possessing antimicrobial activity | LCLAT1, NRDC, LAS1L | HSD17B10 1493/4885SMN1; SMN2 4286/4885MEN1 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.